阿片类使用障碍药物治疗中渴求结局线性混合效应分析的模型选择
Model selection in linear mixed-effects analysis of craving outcomes in a randomized controlled trial of medications for opioid use disorders
基于NCT02032433随机对照试验数据(BUP-NX组n=287,XR-NTX组n=283),对阿片、酒精、兴奋剂及尼古丁渴求的纵向分析显示,非结构化(UN)协方差结构在AIC比较中拟合最优。随访期间四种渴求评分均较基线显著下降,且兴奋剂渴求在特定访视存在治疗组间交互效应。
- Article
- Open access
- Published: 27 October 2026
Scientific Reports (2026) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Identifying an appropriate covariance structure is a critical step in modeling longitudinal changes in polysubstance cravings during medications for opioid use disorders (MOUD) treatment. This study analyzed data from the National Drug Abuse Treatment Clinical Trials Network trial CTN0051, in which participants with opioid use disorders (OUDs) were randomized to receive either buprenorphine-naloxone (BUP-NX; n = 287) or extended-release naltrexone (XR-NTX; n = 283). Cravings for opioids, alcohol, stimulants, and nicotine were assessed at baseline and every four weeks over 36 weeks. Repeated-measures linear mixed models (LMMs) were used to examine longitudinal craving trajectories, with treatment, visit, and treatment-by-visit interaction specified as fixed effects and within-participant correlations among repeated observations modeled through the residual (R-side) covariance structure. Ten commonly used covariance structures were compared using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) to determine optimal model fit. AIC-based comparisons indicated that the unstructured (UN) covariance structure provided the best fit for alcohol, opioid, and stimulant cravings and the second-best fit for nicotine craving. Using the UN covariance structure, craving scores decreased significantly from baseline across all four craving domains during follow-up. Treatment-by-visit interactions were observed for stimulant craving at selected visits, indicating differences between treatment groups in changes from baseline over time. Baseline alcohol and amphetamine use disorders predicted higher alcohol cravings, while baseline depression, amphetamine, and cocaine use disorders predicted greater stimulant cravings; baseline cocaine use disorder also predicted elevated nicotine craving. In conclusion, the UN covariance structure most effectively captured craving trajectories. These findings identify clinical characteristics associated with differences in reported craving; however, their utility for guiding treatment selection or predicting relapse requires prospective validation.
Clinical trial number: NCT02032433.
Abbreviations
- AIC:
-
Akaike Information Criterion
- AL:
-
Alcohol craving
- ANTE:
-
Ante-dependence
- AR:
-
Autoregressive
- ARH:
-
Heterogeneous autoregressive
- ARMA:
-
First-order autoregressive moving average
- AUD:
-
Alcohol use disorder
- BIC:
-
Bayesian Information Criterion
- BUP-NX:
-
Buprenorphine-naloxone
- CBT:
-
Cognitive-behavioral therapy
- CDC:
-
Centers for Disease Control and Prevention
- CS:
-
Compound symmetry
- CSH:
-
Heterogeneous compound symmetry
- CTN:
-
Clinical Trials Network
- HF:
-
Huynh–Feldt
- LMMs:
-
Linear mixed-effects models
- MDD:
-
Major depressive disorder
- MOUD:
-
Medications for opioid use disorders
- NIC:
-
Nicotine craving
- NIDA:
-
National Institute on Drug Abuse
- OP:
-
Opioids craving
- OUD:
-
Opioid use disorder
- SD:
-
Standard deviation
- STM:
-
Stimulant craving
- SUD:
-
Substance use disorder
- TOEP:
-
Banded Toeplitz
- UN:
-
Unstructured
- VAS:
-
Visual analog scales
- VC:
-
Variance components
- XR-NTX:
-
Extended-release naltrexone
Acknowledgements
The information reported here results from secondary analyses of data from NIDA CTN-0051 (Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment), a clinical trial conducted by the NIDA Clinical Trials Network. NIDA databases and information are available at https://datashare.nida.nih.gov.
Funding
No funding source is given for the present paper.
Author information
Authors and Affiliations
Department of Biobehavioral Health & Nursing Science, College of Nursing, University of South Carolina, 1601 Greene St, Columbia, 29208, SC, USA
Kesheng Wang, Donna M. Kazemi, Pamela J. Wright & Phyllis A. Raynor
Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 921 Assembly St, Columbia, 29208, SC, USA
Kesheng Wang & Jiajia Zhang
Authors
- Kesheng Wang
- Donna M. Kazemi
- Pamela J. Wright
- Phyllis A. Raynor
- Jiajia Zhang
Corresponding author
Correspondence to Kesheng Wang.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
The original CTN-0051 study (Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment) was approved by the institutional review boards at participating sites, and participants provided written informed consent. The present secondary analysis was exempt from IRB review due to secondary data analysis using a publicly accessible database.
Consent for publication
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Wang, K., Kazemi, D.M., Wright, P.J. et al. Model selection in linear mixed-effects analysis of craving outcomes in a randomized controlled trial of medications for opioid use disorders. Sci Rep (2026). https://doi.org/10.1038/s41598-026-77858-y
Received: 07 February 2026
Accepted: 22 October 2026
Published: 27 October 2026
DOI: https://doi.org/10.1038/s41598-026-77858-y
Keywords
来源:Nature 健康护理主题 · nature.com